0001709913-21-000001.txt : 20210104
0001709913-21-000001.hdr.sgml : 20210104
20210104110759
ACCESSION NUMBER: 0001709913-21-000001
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20210104
DATE AS OF CHANGE: 20210104
EFFECTIVENESS DATE: 20210104
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kryo, Inc.
CENTRAL INDEX KEY: 0001709913
IRS NUMBER: 813741967
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-384171
FILM NUMBER: 21500598
BUSINESS ADDRESS:
STREET 1: 144 TALBERT POINTE DR., SUITE 103
CITY: MOORESVILLE
STATE: NC
ZIP: 28117
BUSINESS PHONE: 877-235-6271
MAIL ADDRESS:
STREET 1: 144 TALBERT POINTE DR., SUITE 103
CITY: MOORESVILLE
STATE: NC
ZIP: 28117
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001709913
Kryo, Inc.
144 TALBERT POINTE DR., SUITE 103
MOORESVILLE
NC
NORTH CAROLINA
28117
877-235-6271
DELAWARE
Kryo, LLC
None
Corporation
true
2016
Todd
Youngblood
c/o Kryo, Inc.
144 Talbert Pointe Dr., Suite 103
Mooresville
NC
NORTH CAROLINA
28117
Executive Officer
Director
Tara
Youngblood
c/o Kryo, Inc.
144 Talbert Pointe Dr., Suite 103
Mooresville
NC
NORTH CAROLINA
28117
Executive Officer
Director
Sulekha
Ramayya
c/o Kryo, Inc.
144 Talbert Pointe Dr., Suite 103
Mooresville
NC
NORTH CAROLINA
28117
Director
Other Technology
Decline to Disclose
- 06b
true
0001709913-20-000002
2020-12-09
false
true
true
In connection with the acquisition of Ebb Therapeutics, Inc. by Kryo, Inc. (the "Company"), the Company entered into a stock purchase agreement providing for the issuance of the Company's preferred stock to an accredited investor.
0
Charles Towne Securities, LLC
172278
Charles Towne Securities, LLC
172278
701 E Bay Street
Suite 405
Charleston
SC
SOUTH CAROLINA
29403
All States
false
20000000
20000000
0
false
1
868000
0
0
Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.
false
Kryo, Inc.
/s/ Tara Youngblood
Tara Youngblood
Chief Executive Officer
2021-01-04